Log In
BCIQ
Print this Print this
 

CLT-28643

  Manage Alerts
Collapse Summary General Information
Company Clanotech AB
DescriptionIntegrin alpha(5)beta(1) antagonist
Molecular Target Integrin alpha(5)beta(1)
Mechanism of ActionIntegrin alpha(5)beta(1) antagonist
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationGlaucoma
Indication DetailsPrevent scarring following glaucoma filtration surgery
Regulatory Designation U.S. - Orphan Drug (Prevent scarring following glaucoma filtration surgery);
EU - Orphan Drug (Prevent scarring following glaucoma filtration surgery)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today